非小细胞肺癌中PDGF-BB表达及其与骨转移的相关性  

Expression of PDGF-BB in non-small cell lung cancer and its relationship with bone metastasis

作　　者：任鹏飞 王弦[2] 李晶晶[1] 琚倩 孟晨旭 龙其河 金像婷 李烦繁[1] REN Peng-fei;WANG Xian;LI Jing-jing;JU Qian;MENG Chen-xu;LONG Qi-he;JIN Xiang-ting;LI Fan-fan(Department of Oncology,the Second Affiliated Hospital of Anhui Medical University,Hefei 230601,China;Department of Pathology,the Second Affiliated Hospital of Anhui Medical University,Hefei 230601,China)

机构地区：[1]安徽医科大学第二附属医院肿瘤科,合肥230601 [2]安徽医科大学第二附属医院病理科,合肥230601

出　　处：《临床与实验病理学杂志》2021年第6期669-673,共5页Chinese Journal of Clinical and Experimental Pathology

基　　金：安徽高校自然科学基金(2019A0258)。

摘　　要：目的探讨血小板衍生生长因子BB(platelet derived growth factor-BB,PDGF-BB)在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达及其与NSCLC骨转移的关系。方法使用酶联免疫吸附法(enzyme linked immunosorbent assay,ELISA)检测87例初诊NSCLC患者血清中PDGF-BB的表达水平,分析其与NSCLC骨转移的相关性。采用免疫组化法检测142例NSCLC手术标本中PDGF-BB的表达,分析其与临床病理特征、骨转移,以及骨转移患者无骨转移生存时间(bone metastasis-free survival,BMFS)的相关性。结果PDGF-BB在初诊NSCLC骨转移组及除外骨转移的远处转移组患者血清中的表达均高于无转移组患者(P<0.05);在既往行根治性手术NSCLC患者原发灶中,Ⅲ期患者的PDGF-BB阳性率高于Ⅰ、Ⅱ期患者(P<0.05);有区域淋巴转移者PDGF-BB的阳性率高于无区域淋巴转移者(P<0.05)。骨转移组PDGF-BB的阳性率为75.41%,高于除外骨转移的远处转移组(40.00%)和无转移组患者(32.14%)(P<0.05);骨转移组中,PDGF-BB阳性患者的中位BMFS为11个月(8.78~13.22个月),小于PDGF-BB阴性患者(中位BMFS 22个月,16.32~27.68个月)(P<0.05)。结论PDGF-BB与NSCLC患者骨转移的发生、发展及预后密切相关,对NSCLC骨转移的早期诊断及监测具有重要意义。Purpose To investigate the expression of platelet derived growth factor-BB(PDGF-BB)in non-small cell lung cancer(NSCLC)and its relationship with bone metastasis in NSCLC.Methods The expression level of PDGF-BB in the serum of 87 patients with primary NSCLC was measured by enzyme linked immunosorbent assay(ELISA),and its correlation with the occurrence of bone metastasis in NSCLC was analyzed.Immunohistochemistry was used to detect the expression of PDGF-BB in 142 surgical specimens of NSCLC patients and analyze its correlation with clinicopathological characteristics,the occurrence of bone metastasis,and the bone metastasis-free survival(BMFS)of patients with bone metastasis.Results The expression of PDGF-BB in the serum of newly diagnosed NSCLC bone metastasis group and distant the metastasis excluding bone metastases was higher than that in the non-metastasis group(P<0.05).Among the primary foci of NSCLC patients who had undergone previous radical surgery,immunohistochemical results showed that the positive rate of PDGF-BB in stageⅢpatients was significantly higher than that in stageⅠandⅡpatients(P<0.05).The PDGF-BB positivity rate in patients with regional lymphatic metastases was higher than that in patients without regional lymphatic metastases(P<0.05).The PDGF-BB positive rate in the bone metastasis group was 75.41%,which was higher than that in the distant metastasis group excluding bone metastasis(40.00%)and in the non-metastasis group(32.14%,P<0.05).In the bone metastasis group,the median BMFS of PDGF-BB positive patients was 11 months(8.78-13.22 months),which was lower than that of PDGF-BB-negative patients(22 months,16.32-27.68 months,P<0.05).Conclusion PDGF-BB is closely related to the development and prognosis of bone metastases in NSCLC patients,and is of great significance for the early diagnosis and monitoring of bone metastases in NSCLC.

关 键 词：肺肿瘤 非小细胞肺癌 PDGF-BB 骨转移 无骨转移生存时间 

分 类 号：R734.2[医药卫生—肿瘤]